Merck Partner Joins Forces With Emergent Bio To Increase Access To Ebola Treatment

Emergent BioSolutions Inc EBS has agreed to create a collaboration with Ridgeback Biotherapeutics to expand the availability of Ebanga (Ansuvimab-zykl).
FDA approved Ebanga in December 2020 for Ebola.
Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga in the U.S. and Canada.
Ridgeback Bio will serve as the global access partner for Ebanga, ensuring it remains available to patients in endemic countries free of charge through Ridgeback Bio's compassionate use program.
Read Next: White House Outlines New Monkeypox Vaccine Strategy: What You Need To Know.
Ebanga is a monoclonal antibody with antiviral activity provided through a single injection.
It was developed for Ebola by Ridgeback Bio under the National Institute of Allergy and Infectious Diseases license.
Ridgeback Bio provided funding and operational support for clinical testing. Additional funding was received under contracts with the Biomedical Advanced Research and Development Authority for late-stage manufacturing and regulatory activities.
Price Action: EBS shares closed at $33.45 on Thursday.

Momentum26.16

Growth1.63

QualityNot Available

Value65.73

Short

Medium

Long